Symptomtext
two doses of Fluzone High Dose QIV within the same season with no reported adverse event; Initial information received on 09-Nov-2022 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 84 years old female patient who recieved two doses of fluzone high dose qiv (INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE)within the same season with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included COVID-19 VACCINE (COVID-19 VACCINE) for Immunisation. On 28-Oct-2022 the patient received a dose of 0.7 ml of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (formulation, strength: unknown) lot UJ932AB via unknown route in unknown administration site as immunization. On 09-Nov-2022, the patient received a dose of 0.7 ml of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (formulation, strength: unknown) lot UJ917AB, Expiration date: 30-Jun-2023 via unknown route in the left deltoid as immunization. On 09-NOV-2022 the patient received another dose (total 2 doses) of fluzone high dose qiv within the same season with no reported adverse event (extra dose administered) 12 days following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE. The patient was not using the product at the time of report. Action taken was not applicable. It was not reported if the patient received a corrective treatment for the event (two doses of Fluzone High Dose QIV within the same season with no reported adverse event). At time of reporting, the outcome was Unknown for the event This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.